・Study includes both antifibrotic-treated and untreated patients; top-line data expected in H1 2027
・First-in-class PRS inhibitor being developed as a potential new therapeutic option for IPF BARCELONA, Spain and SEOUL, South Korea, Sept. 24, 2026 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Changjae Lee) announced that it presented a poster on the baseline characteristics of all 104 patients enrolled in the global Phase 2 clinical trial of its idiopathic pulmonar…READ FULL ARTICLE
